Topics
Pediatric-type diffuse high-grade gliomas | Overall management | Diffuse hemispheric gliomas
Home > Publications > Topics > Pediatric-type diffuse high-grade gliomas > Overall management > Diffuse hemispheric gliomas
Le Rhun E, Bink A, Felsberg J, Gramatzki D, Brandner S, Benhamida
JK, Wick A, Tonn JC, Mohme M, Tabatabai G, Capper D, Snuderl M,
Razis E, Ronellenfitsch MW, Neidert N, Ng HK, Pohl U, Bale T,
Quach S, Rieger D, Schüller U, Onken J, Drüschler K,
Maurage CA, Regli L, Healy E, Graham M, Hortobagyi T, Paine S,
Bridges L, Lausova T, Medici V, Sievers P, Schrimpf D, Wick W,
Sahm F, Reifenberger G, von Deimling A, Weller M; H3 G34 DHG Study
Group.
The clinical and molecular
landscape of diffuse hemispheric glioma, H3 G34-mutant.
Neuro
Oncol. 2025 Jan 22:noaf015. doi:
10.1093/neuonc/noaf015. PMID:
39842935. Observational study. ˍ
Bagchi A, Chiang J, Pinto S, Dhanda S, Gajjar A.
Infant-Type
Hemispheric Gliomas: A Review of Clinical, Radiologic,
Histopathologic, and Molecular Features.
J
Natl Compr Canc Netw. 2025 Nov 1;23(11):e257064. doi:
10.6004/jnccn.2025.7064. PMID:
41213248. Review. ˍ
Tlais D, Zhang Q, Roach JT, Tinkle CL, Lin T, Li X, Mostafa A,
Moreira DC, McNall-Knapp RY, Rush SZ, Le BH, Sinno S, Ramnarayan
A, Ginn KF, Partap S, Onar-Thomas A, Furtado LV, Bag AK, Chiang J.
Pediatric H3 G34-mutant diffuse
hemispheric glioma: clinical, imaging and molecular prognostic
factors, MGMT expression, and temozolomide response.
Acta
Neuropathol. 2026 Mar 2;151(1):22. doi:
10.1007/s00401-026-02992-w. PMID:
41770225. ˍ